Joseph Capper Purchases 25,000 Shares of TELA Bio (NASDAQ:TELA) Stock

TELA Bio, Inc. (NASDAQ:TELA) Director Joseph Capper purchased 25,000 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was bought at an average price of $1.22 per share, for a total transaction of $30,500.00. Following the acquisition, the director owned 179,827 shares in the company, valued at $219,388.94. The trade was a 16.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

TELA Bio Trading Down 3.1%

Shares of TELA stock traded down $0.04 on Friday, reaching $1.25. 479,477 shares of the stock were exchanged, compared to its average volume of 186,919. The stock has a market cap of $56.43 million, a P/E ratio of -1.62 and a beta of 1.36. The company has a quick ratio of 2.38, a current ratio of 2.99 and a debt-to-equity ratio of 8.82. The firm has a 50 day moving average of $0.79 and a two-hundred day moving average of $0.79. TELA Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.69.

TELA Bio (NASDAQ:TELA) last issued its earnings results on Monday, August 10th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. The firm had revenue of $19.29 million during the quarter, compared to analyst estimates of $20.01 million. On average, research analysts anticipate that TELA Bio, Inc. will post -0.76 EPS for the current year.

Hedge Funds Weigh In On TELA Bio

Hedge funds have recently made changes to their positions in the business. Perkins Capital Management Inc. grew its stake in shares of TELA Bio by 1.5% during the first quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company’s stock valued at $879,000 after acquiring an additional 20,910 shares in the last quarter. WealthTrust Axiom LLC lifted its stake in shares of TELA Bio by 39.1% in the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock worth $381,000 after acquiring an additional 90,650 shares in the last quarter. UP Strategic Wealth Investment Advisors LLC acquired a new position in shares of TELA Bio in the second quarter worth about $91,000. BlackRock Inc. purchased a new position in TELA Bio in the second quarter valued at about $281,000. Finally, Stonepine Capital Management LLC purchased a new position in TELA Bio in the second quarter valued at about $1,996,820. Hedge funds and other institutional investors own 94.35% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $2.20.

TELA Bio Company Profile

TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.

The company’s principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.